5. The formulation of claim 4, wherein said pharmaceutical compression aid is selected from the group consisting of lactose, cellulose, dibasic calcium phosphate dihydrate, calcium sulfite dihydrate, tricalcium phosphate and compressible sugar.

9. The formulation of claim 1, wherein said polymeric film is a polymer selected from the group consisting of cellulose esters, polyvinyl acetate phthalate, methacrylic acid copolymers and any mixtures thereof.

10. Cancel

12. The formulation of claim 1, wherein said polymeric film further comprises an agent selected from the group consisting of anti-tacking agents, colorants and mixtures thereof.

13. Cancel

15. The formulation of claim 1, wherein said pharmaceutical active is selected from the group consisting of risedronate, alendronate, riluzole, sulfonylureas including glyburide, chlorpropamide, tolbutamide, glimepiride, acarbose, alglucerase, miglitol, nateglinide, pimagidine, pioglitazone, pramlintide, repaglinide, rosiglitazone, troglitazone, hypoglycemic benzenesulfonamido pyrimidines, buformin, phenformin and 1,2-Biguanides.

17. An extended release pharmaceutical active formulation comprising;

- a capsule, tablet, pellet or bead of about 5-95% by weight pharmaceutical active;

- an encasement coat comprising one or more layers of a polymeric film encasing said capsule, tablet, pellet or bead, said encasement coat soluble in a pH of above about 5.0 and comprising about 5 up to less than 50% by weight polymer and about 0.5%-30% by weight plasticizer comprising polyethylene glycol,

- wherein said formulation provides over 12 hours of extended release of said active in the bloodstream.

18. The formulation of claim 17, wherein said capsule, tablet, pellet or bead additionally comprises;

- about 0-60% by weight pharmaceutical compression aid; and
- about 0-50% by weight pharmaceutical extrusion aid.

19. Cancelled

20. The formulation of claim 18, wherein said pharmaceutical compression aid is selected from the group consisting of lactose, cellulose, dibasic calcium phosphate dihydrate, calcium sulfite dihydrate, tricalcium phosphate and compressible sugar.

21. The formulation of claim 17, wherein said polymeric film is a polymer selected from the group consisting of cellulose esters, polyvinyl acetate phthalate, methacrylic acid copolymers and any mixtures thereof.

23. An extended release pharmaceutical active formulation comprising;

a capsule, tablet, pellet or bead of pharmaceutical active comprising;

- about 5-95% by weight pharmaceutical active;
- about 0-60% by weight pharmaceutical compression aid;
- about 0-50% by weight pharmaceutical extrusion aid; and
- an encasement coat comprising one or more layers of a polymeric film encasing said pharmaceutical active, said encasement coat soluble in a pH of above about 5.0 and comprising about 5 up to less than 50% by weight polymer and about 0.5%-30% by weight plasticizer comprising polyethylene glycol,
- wherein said formulation provides over 12 hours of extended release of said active in the bloodstream.

31. A method for making an extended release pharmaceutical active formulation comprising;

- compressing about 5-95% by weight pharmaceutical active into tablets, pellets or beads;
- encasing said tablets, pellets or beads in an encasement coat comprising one or more layers of a polymeric film encasing said capsule, tablet, pellet or bead, said encasement coat soluble in a pH of above about 5.0 and comprising about 5 up to less than 50% by weight polymer and about 0.5%-30% by weight plasticizer comprising polyethylene glycol,